---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-033476"
form_type: "8-K"
ticker: "ACET"
cik: "0001720580"
company_name: "Adicet Bio, Inc."
filed_at: "2024-03-19T23:59:59+00:00"
generated_at: "2026-06-04T13:33:00.704342+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Adicet Bio reports Q4 net loss $29.5M, extends cash runway into 2H 2026; IND cleared for ADI-001 in lupus nephritis

## Summary
- Net loss $29.5M ($0.69/share) in Q4 2023 vs $29.9M ($0.72/share) in Q4 2022; full-year net loss $142.7M ($3.31/share) vs $69.8M ($1.70/share).
- Cash and equivalents $159.7M at Dec 31, 2023; raised net $91.8M from public offering and $19.3M from ATM in Jan 2024, extending runway into 2H 2026.
- FDA cleared IND for ADI-001 in lupus nephritis in Dec 2023; Phase 1 trial initiation expected in Q2 2024 with preliminary data in Q4 2024/Q1 2025.
- On track to file IND for ADI-270 in renal cell carcinoma in Q2 2024; Phase 1 clinical data expected in first half of 2025.
- Appointed Benjamin Hsu, M.D., Ph.D., as VP Clinical Development - Autoimmune, to lead autoimmune cell therapy programs.

## SEC filing metadata
- accession: 0000950170-24-033476
- form_type: 8-K
- ticker: ACET
- cik: 0001720580
- company_name: Adicet Bio, Inc.
- filed_at: 2024-03-19T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1720580/000095017024033476/0000950170-24-033476-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1720580/000095017024033476/acet-20240319.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-033476
- JSON: https://secwatch.observer/filing/0000950170-24-033476.json
- Plain text: https://secwatch.observer/filing/0000950170-24-033476.txt

## Key facts
- Earnings Releases
  Adicet Bio, Inc. reported fourth quarter and year ended December 31, 2023 results: net income Net loss for the three months ended December 31, 2023 was $29.5 million, or a net loss of $0.69 per basic and diluted sh, EPS $0.69 per basic and diluted share.
  - Period: fourth quarter and year ended December 31, 2023
  - Net income: Net loss for the three months ended December 31, 2023 was $29.5 million, or a net loss of $0.69 per basic and diluted sh
  - EPS: $0.69 per basic and diluted share
  - Result: reported results
  source text: On March 19, 2024, Adicet Bio, Inc. announced its financial results for the quarter and year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1720580/000095017024033476/0000950170-24-033476-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.